EDSA (Edesa Biotech) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Edesa Biotech EBITDA Margin %?

Edesa Biotech EDSA +5.58% 26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Edesa Biotech ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Edesa Biotech's EBITDA for the three months ended in Mar. 2026 was $-4.21 Mil. Edesa Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Edesa Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Edesa Biotech (NAS:EDSA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Edesa Biotech EBITDA Margin % Related Terms

Edesa Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech EBITDA Margin % Chart

Edesa Biotech Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

Edesa Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

EDSA vs PMVP, IMA, ENTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Edesa Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's EBITDA Margin % falls into.

Save Embed

26GF Score

Edesa Biotech Inc EDSA

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Edesa Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Edesa Biotech's EBITDA Margin % for the fiscal year that ended in Sep. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Sep. 2025 )	/	Revenue (A: Sep. 2025 )
	=	-7.008	/	0
	=	%

Edesa Biotech's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-4.205	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Edesa Biotech (EDSA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edesa Biotech and its competitors. According to the industry distribution chart, Edesa Biotech ranks #999999 out of 945 companies in the Biotechnology industry.

Is Edesa Biotech's EBITDA Margin % too high?

Edesa Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, Edesa Biotech ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.

How does Edesa Biotech's EBITDA Margin % compare to PMVP and IMA?

According to the Biotechnology industry distribution chart, Edesa Biotech ranks #999999 out of 945 companies for EBITDA Margin %. This places Edesa Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Edesa Biotech stock overvalued right now?

Edesa Biotech (EDSA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies PMVP IMA ENTX MNOV PDSB INKT ACRV BYSI BSEM TCRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6

Website https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

26GF Score

Get the complete analysis for EDSA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95

Price

View EDSA Analysis

See EBITDA Margin % data for all stocks →